STAT+: BeOne wins FDA approval in lymphoma race

STAT PlusNewsletterThe Readout BeOne wins FDA approval in lymphoma race Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Meghana KeshavanMay 14, 2026 Biotech Correspondent Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Biotech’s cell therapy boom keeps expanding beyond cancer: CREATE Medicines just raised $122 million to advance its in vivo CAR-T for autoimmune disease into the clinic.Advertisement Meanwhile, the Trump administration is searching for a new FDA commissioner, setting up a politically fraught fight over the agency’s future direction. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Health Tech Newsletter May 14, 2026 STAT Plus: Why big digital health players are missing from Medicare’s chronic care experiment Biotech May 14, 2026 STAT Plus: Biogen’s tau-targeting Alzheimer’s drug posts mixed results in mid-stage study Advertisement Exclusive May 14, 2026 STAT Plus: CREATE Medicines, a biotech company developing CAR-T therapies, raises $122 million Biotech May 14, 2026 STAT Plus: Regenxbio says Duchenne gene therapy succeeded in clinical trial, paving way for FDA submission Adam's Biotech Scorecard May 14, 2026 STAT Plus: ‘No drama’ Diamantas should serve biotech well as acting FDA chief Subscriber Picks